Worldwide Seroprevalence and Risk Factors of Toxoplasma gondii Exposure Among Students: A Systematic Review and Meta-Analysis.

Zoonoses Public HealthJul 22, 2026 (epub)
Clinical ResearchPreventive Medicine / Public HealthInfectious DiseasesOpen access

Sara Lesani, Mohammad Javad Boozhmehrani

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed the global seroprevalence of Toxoplasma gondii among students, analyzing data from 50 studies involving 32,054 participants across 24 countries. The overall pooled seroprevalence was found to be 14.0% (95% CI 11.7-16.6). Significant risk factors included contact with cats, soil exposure, and consumption of undercooked meat.

Key findings

  • The pooled global seroprevalence of T. gondii among students was 14.0% (95% CI 11.7-16.6).
  • Seroprevalence was highest in primary school students at 28.5% (95% CI 20.6-37.7).
  • Contact with cats was associated with a relative risk of 1.888 (p < 0.001).
  • Soil exposure had a relative risk of 1.940 (p < 0.001).

Why it matters

Understanding the seroprevalence and risk factors for T. gondii exposure in students is crucial for developing targeted public health strategies. This knowledge can help mitigate the risk of congenital and neurological complications associated with the infection.

Source

PubMed · PMID 42487234Free full text on PubMed Central

Published in Zoonoses Public Health. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Preventive Medicine / Public Health

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.